Several mechanisms of resistance to VEGF-targeted therapy have been suggested; among them are a complex interaction between tumor cells and stroma, an increased aggressiveness of the tumor caused by hypoxia (and thus new mutations), hypoxia-induced increase of cancer stem cells, and an activation of alternative pro-angiogenic signaling pathways [50]. This evidence concerns the gene VEGFA and neoplasm.